955 related articles for article (PubMed ID: 16007538)
1. Long-term follow-up of asymptomatic HIV-infected patients who discontinued antiretroviral therapy.
Fernández Guerrero ML; Rivas P; Molina M; Garcia R; De Górgolas M
Clin Infect Dis; 2005 Aug; 41(3):390-4. PubMed ID: 16007538
[TBL] [Abstract][Full Text] [Related]
2. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
[TBL] [Abstract][Full Text] [Related]
3. Treatment interruption of highly active antiretroviral therapy in patients with nadir CD4 cell counts >200 cells/mm3.
Toulson AR; Harrigan R; Heath K; Yip B; Brumme ZL; Harris M; Hogg RS; Montaner JS
J Infect Dis; 2005 Nov; 192(10):1787-93. PubMed ID: 16235178
[TBL] [Abstract][Full Text] [Related]
4. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4+ T cell decline in human immunodeficiency virus-infected patients: implications for intermittent therapeutic strategies.
Tebas P; Henry K; Mondy K; Deeks S; Valdez H; Cohen C; Powderly WG
J Infect Dis; 2002 Sep; 186(6):851-4. PubMed ID: 12198623
[TBL] [Abstract][Full Text] [Related]
5. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy.
Smith CJ; Sabin CA; Youle MS; Kinloch-de Loes S; Lampe FC; Madge S; Cropley I; Johnson MA; Phillips AN
J Infect Dis; 2004 Nov; 190(10):1860-8. PubMed ID: 15499544
[TBL] [Abstract][Full Text] [Related]
6. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
[TBL] [Abstract][Full Text] [Related]
7. Extended antiretroviral treatment interruption in HIV-infected patients with long-term suppression of plasma HIV RNA.
Achenbach CJ; Till M; Palella FJ; Knoll MD; Terp SM; Kalnins AU; Murphy RL
HIV Med; 2005 Jan; 6(1):7-12. PubMed ID: 15670246
[TBL] [Abstract][Full Text] [Related]
8. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
Moore RD; Keruly JC
Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
[TBL] [Abstract][Full Text] [Related]
9. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
[TBL] [Abstract][Full Text] [Related]
10. Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trial.
Miro JM; Lopez JC; Podzamczer D; Peña JM; Alberdi JC; Martínez E; Domingo P; Cosin J; Claramonte X; Arribas JR; Santín M; Ribera E;
Clin Infect Dis; 2006 Jul; 43(1):79-89. PubMed ID: 16758422
[TBL] [Abstract][Full Text] [Related]
11. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up.
Resino S; Resino R; Micheloud D; Gurbindo Gutiérrez D; Léon JA; Ramos JT; Ciria L; de José I; Mellado J; Muñoz-Fernández A;
Clin Infect Dis; 2006 Mar; 42(6):862-9. PubMed ID: 16477566
[TBL] [Abstract][Full Text] [Related]
12. Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study.
Lohse N; Kronborg G; Gerstoft J; Larsen CS; Pedersen G; Pedersen C; Sørensen HT; Obel N
Clin Infect Dis; 2006 Jan; 42(1):136-44. PubMed ID: 16323104
[TBL] [Abstract][Full Text] [Related]
13. Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently <500 copies/mL during treatment with antiretroviral drugs.
Le Moing V; Thiébaut R; Chêne G; Sobel A; Massip P; Collin F; Meyohas M; Al Kaïed F; Leport C; Raffi F;
HIV Med; 2007 Apr; 8(3):156-63. PubMed ID: 17461859
[TBL] [Abstract][Full Text] [Related]
14. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
[TBL] [Abstract][Full Text] [Related]
15. CD4+ cell-count-guided treatment interruptions in chronic HIV-infected patients with good response to highly active antiretroviral therapy.
Boschi A; Tinelli C; Ortolani P; Moscatelli G; Morigi G; Arlotti M
AIDS; 2004 Dec; 18(18):2381-9. PubMed ID: 15622314
[TBL] [Abstract][Full Text] [Related]
16. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
Lapadula G; Torti C; Maggiolo F; Casari S; Suter F; Minoli L; Pezzoli C; Di Pietro M; Migliorino G; Ouiros-Roldan E; Ladisa N; Sighinolfi L; Costarelli S; Carosi G;
Antivir Ther; 2007; 12(6):941-7. PubMed ID: 17926648
[TBL] [Abstract][Full Text] [Related]
17. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.
Hecht FM; Wang L; Collier A; Little S; Markowitz M; Margolick J; Kilby JM; Daar E; Conway B; Holte S;
J Infect Dis; 2006 Sep; 194(6):725-33. PubMed ID: 16941337
[TBL] [Abstract][Full Text] [Related]
18. CD4 cell-monitored treatment interruption in patients with a CD4 cell count > 500 x 106 cells/l.
Mussini C; Bedini A; Borghi V; Guaraldi G; Esposito R; Barchi E; Enilia R; Cozzi-Lepri A; Philips AN; Ortolani P; Bratt G; Eriksson LE; Sighinolfi L; Cossarizza A; d'Arminio Monforte A; De Luca A; Di Giambenedetto S; Antinori A;
AIDS; 2005 Feb; 19(3):287-94. PubMed ID: 15718839
[TBL] [Abstract][Full Text] [Related]
19. Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort study.
Sterling TR; Chaisson RE; Keruly J; Moore RD
J Infect Dis; 2003 Dec; 188(11):1659-65. PubMed ID: 14639536
[TBL] [Abstract][Full Text] [Related]
20. Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Côte d'Ivoire.
Adjé-Touré CA; Cheingsong R; Garcìa-Lerma JG; Eholié S; Borget MY; Bouchez JM; Otten RA; Maurice C; Sassan-Morokro M; Ekpini RE; Nolan M; Chorba T; Heneine W; Nkengasong JN
AIDS; 2003 Jul; 17 Suppl 3():S49-54. PubMed ID: 14565609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
